ASND

Ascendis Pharma AS (ASND)

Ascendis Pharma AS

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ASND

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/17	05:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ASND	Ascendis Pharma AS
2024/05/15	03:37	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ASND	Ascendis Pharma AS
2024/05/15	03:31	GlobeNewswire Inc.	Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism	NASDAQ:ASND	Ascendis Pharma AS
2024/05/13	21:30	GlobeNewswire Inc.	Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial	NASDAQ:ASND	Ascendis Pharma AS
2024/05/09	21:30	GlobeNewswire Inc.	Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024	NASDAQ:ASND	Ascendis Pharma AS
2024/05/03	05:01	GlobeNewswire Inc.	Ascendis Pharma Reports First Quarter 2024 Financial Results	NASDAQ:ASND	Ascendis Pharma AS
2024/04/26	05:46	GlobeNewswire Inc.	Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024	NASDAQ:ASND	Ascendis Pharma AS
2024/04/24	21:30	GlobeNewswire Inc.	United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism	NASDAQ:ASND	Ascendis Pharma AS
2024/03/08	01:31	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/03/06	11:39	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/03/05	22:14	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/03/05	22:04	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/03/05	21:37	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/03/05	05:17	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/03/05	05:07	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/03/05	04:54	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/03/05	04:36	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/03/05	04:24	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/03/04	22:30	GlobeNewswire Inc.	Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024	NASDAQ:ASND	Ascendis Pharma AS
2024/03/02	01:00	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/03/01	07:13	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/02/29	06:49	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/02/28	07:45	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/02/22	05:17	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/02/17	07:16	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/02/17	07:15	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/02/17	07:14	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/02/15	06:07	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ASND	Ascendis Pharma AS
2024/02/15	01:40	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/02/14	23:17	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ASND	Ascendis Pharma AS